Paradigm uncovers strong regional iPPS signal despite halted Phase 3 trial

• ROW iPPS patients recorded 1.105 points more pain relief than placebo at Day 112
• Statistically significant improvements also emerged in function, WOMAC pain and PGIC
• The post hoc analysis covered 16 sites across Australia, Hong Kong and Moldova
• The overall futility outcome remains unchanged and PARA_OA_012 will not proceed